Compass Therapeutics (CMPX) Amortization of Deferred Charges (2021 - 2026)
Compass Therapeutics recorded quarterly Amortization of Deferred Charges of -$206000.0 in Q1 2026, up 82.78% quarter-over-quarter from -$1.2 million in Q4 2025, and down 892.31% year-over-year from $26000.0 in Q1 2025.
Compass Therapeutics' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at -$206000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 892.31% year-over-year to -$206000.0; the TTM figure through Mar 2026 stood at -$1.9 million (down 52.52% YoY), while the FY2025 annual figure was -$1.7 million, down 1.33% from the prior year.
- Amortization of Deferred Charges came in at -$206000.0 for Q1 2026 at Compass Therapeutics, up from -$1.2 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $110000.0 in Q2 2022 to a low of -$1.2 million in Q4 2025.
- A 5-year average of -$472312.5 and a median of -$375500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges plunged 10283.33% in 2022 and surged 106.91% in 2025, its largest moves.
- Compass Therapeutics' Amortization of Deferred Charges stood at -$611000.0 in 2022, then sank by 32.9% to -$812000.0 in 2023, then soared by 66.75% to -$270000.0 in 2024, then sank by 342.96% to -$1.2 million in 2025, then soared by 82.78% to -$206000.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered -$206000.0, -$1.2 million, and -$375000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -206,000.00 |
| Mar 31, 2026 | -206,000.00 |
| Dec 31, 2025 | -1.20 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -375,000.00 |
| Sep 30, 2025 | -375,000.00 |
| Jun 30, 2025 | -128,000.00 |
| Jun 30, 2025 | -128,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Dec 31, 2024 | -270,000.00 |
| Dec 31, 2024 | -270,000.00 |
| Sep 30, 2024 | -278,000.00 |
| Sep 30, 2024 | -278,000.00 |
| Jun 30, 2024 | -727,000.00 |
| Jun 30, 2024 | -727,000.00 |
| Mar 31, 2024 | -376,000.00 |
| Mar 31, 2024 | -376,000.00 |
| Dec 31, 2023 | -812,000.00 |
| Dec 31, 2023 | -812,000.00 |
| Sep 30, 2023 | -786,000.00 |
| Sep 30, 2023 | -786,000.00 |
| Jun 30, 2023 | -1.04 Mn |
| Jun 30, 2023 | -1.04 Mn |
| Mar 31, 2023 | -593,000.00 |
| Mar 31, 2023 | -593,000.00 |
| Dec 31, 2022 | -611,000.00 |
| Dec 31, 2022 | -611,000.00 |
| Sep 30, 2022 | -300,000.00 |
| Sep 30, 2022 | -300,000.00 |
| Jun 30, 2022 | 110,000.00 |
| Jun 30, 2022 | 110,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Sep 30, 2021 | 13,000.00 |